Losartan Competitively Inhibits CYP2C8-Dependent Paclitaxel Metabolism in Vitro
-
- Mukai Yuji
- Division of Clinical Pharmacology, Hokkaido Pharmaceutical University School of Pharmacy
-
- Toda Takaki
- Division of Clinical Pharmacology, Hokkaido Pharmaceutical University School of Pharmacy
-
- Hayakawa Toru
- Division of Pharmacotherapy, Hokkaido Pharmaceutical University School of Pharmacy
-
- Eliasson Erik
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital Karolinska Institute
-
- Rane Anders
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital Karolinska Institute
-
- Inotsume Nobuo
- Division of Clinical Pharmacology, Hokkaido Pharmaceutical University School of Pharmacy
書誌事項
- タイトル別名
-
- Losartan Competitively Inhibits CYP2C8-Dependent Paclitaxel Metabolism <i>in Vitro</i>
この論文をさがす
抄録
The present study aimed to characterize the inhibitory effects of losartan, an angiotensin II receptor blocker, on CYP2C8. Inhibition experiments were based on human lymphoblast-expressed recombinant CYP2C8 (rCYP2C8) and paclitaxel as a CYP2C8 substrate. The disappearance of paclitaxel (initial concentration: 7.5 µmol/L) was monitored over time at different concentrations of losartan (0, 100, 500 and 1000 µmol/L). For Dixon and Cornish–Bowden plots, various concentrations of losartan (final concentration: 0, 50, 100 and 250 µmol/L) and paclitaxel (final concentration: 3.75, 7.5 and 15 µmol/L) were used. Losartan exhibited significant inhibitory effects on paclitaxel disappearance at losartan concentrations of ≥100 µmol/L (p<0.05). Losartan at 50 µmol/L inhibited the disappearance of paclitaxel by about 60%. Both plots showed that losartan exerted competitive inhibition of rCYP2C8, and its apparent Ki value was estimated to be 40.7 µmol/L. The degree of inhibition (R value) for rCYP2C8 after oral administration of losartan (100 mg) was estimated to be 1.2, using the maximum hepatic input total blood concentration (7.3 µmol/L). The present results show that losartan acts as a competitive inhibitor of CYP2C8-dependent drug metabolism in vitro. Subjects with a low clearance of losartan, resulting in a high average systemic blood concentration of losartan after repeated oral administration, should be carefully monitored for possible adverse reactions during co-medication with CYP2C8 substrate drugs.
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 37 (9), 1550-1554, 2014
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204633753472
-
- NII論文ID
- 130004684797
-
- NII書誌ID
- AA10885497
-
- COI
- 1:STN:280:DC%2BC2M%2FmvFKgsQ%3D%3D
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 025737048
-
- PubMed
- 25177037
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可